# Risankizumab

## Skyrizi inj 150mg/1mL

##### 臨採

| TAH Drug Code      | [ISKY1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISKY1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Psoriasis: For adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Psoriatic Arthritis: For adults with active psoriatic arthritis, either alone or in combination with conventional disease-modifying antirheumatic drugs (cDMARDs), and who have had an inadequate response or are intolerant to DMARDs. Palmoplantar Pustulosis: For adults with moderate to severe palmoplantar pustulosis who have not responded adequately or are intolerant to conventional therapy. Crohn’s Disease: For individuals aged 16 and older with moderate to severe Crohn’s disease who have had an inadequate response, lost response, are intolerant to, or are unsuitable for conventional or biologic therapy. |
| Dosing             | Psoriasis: 150 mg subcutaneous injection at week 0, week 4, then every 12 weeks. Psoriatic Arthritis: 150 mg subcutaneous injection at week 0, week 4, then every 12 weeks. Palmoplantar Pustulosis: 150 mg subcutaneous injection at week 0, week 4, then every 12 weeks. Crohn’s Disease: Induction (IV formulation): 600 mg IV at week 0, week 4, and week 8. Maintenance (SC formulation): For responders to induction, 360 mg SC at week 12 and every 8 weeks thereafter. The safety and efficacy of Skyrizi have not been established for (1) Psoriasis, psoriatic arthritis, or palmoplantar pustulosis in patients under 18 years. (2) Crohn's disease in patients under 16 years.                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | History of serious hypersensitivity reaction to risankizumab or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common: Injection site disorder (1.5-5.6%), Tinea (1.1%), Dyslipidemia, Abdominal pain (5.8-8.5%), Anemia (4.5-4.9%), Antibody development (3.4-24%), Arthralgia (5-9.2%), Arthropathy (0.6-3.5%), Backache (1.9-4.2%), Headache (3.5-6.6%), Urinary tract infectious disease (0.6-3.5%), Upper respiratory infection (10.6-13%), Fatigue (2.5%), Fever (2.6-4.9%). Serious: Injury of liver, Anaphylaxis, Hypersensitivity reaction (2.3%), Tuberculosis, Infectious disease (22.1-36.6%)                                                                                                                                                                                                                                                 |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/risankizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

